Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.56 |
| ▸ | ALOX5AP | P20292 | 17/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 11/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12014953 | 0.93 | PTGES2 (0.57) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 | |
| SCHEMBL167199 | 0.92 | PTGES2 (0.66) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 | |
| SCHEMBL10264786 | 0.91 | PTGES2 (0.56) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 | |
| SCHEMBL1255386 | 0.89 | PTGES2 (0.56) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 | |
| SCHEMBL12510116 | 0.89 | PTGES2 (0.44) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 | |
| SCHEMBL13623140 | 0.88 | ALOX5AP (0.55) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 | |
| SCHEMBL13886900 | 0.86 | ALOX5AP (0.65) | ALOX5APALOX5CYP2C9CYP3A4LTC4S | |
| SCHEMBL169316 | 0.85 | PTGES2 (0.50) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 | |
| SCHEMBL1253718 | 0.84 | ALOX5AP (0.68) | ALOX5APALOX5CYP2C9LTC4SPTGS1 | |
| SCHEMBL13415384 | 0.84 | PTGES2 (0.68) | PTGES2ALOX5APALOX5CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285803-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | Amira Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2010068311-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | disclosed |
| WO-2018152405-A1 | REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR | AUTOIMMUNE PHARMA LLC (US) | 2018-08-23 | — | — | WO | disclosed |
| US-8841295-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841295-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841295-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8772495-B2 | 5-lipoxygenase-activating protein inhibitor | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772495-B2 | 5-lipoxygenase-activating protein inhibitor | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772495-B2 | 5-lipoxygenase-activating protein inhibitor | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8710081-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2007056021-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056228-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056220-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056220-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056228-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056021-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | PTGES2 29/4885ALOX5AP 4/4885ALOX5 1/4885 |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | PTGES2 21/4885ALOX5AP 35/4885ALOX5 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.